Author:
Kang Connie,Syed Yahiya Y.
Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. MYR Pharmaceuticals. MYR Pharmaceuticals receives Conditional Marketing Authorization by the European Commission for HEPCLUDEX® [media release]. 4 Aug 2020. https://www.prnewswire.com.
2. European Medicines Agency. Hepcludex (bulevirtide) powder for solution for injection: EU summary of product characteristics. 2020. https://ec.europa.eu. Accessed 31 Aug 2020.
3. Bogomolov P, Alexandrov A, Voronkova N, et al. Treatment of chronic hepatitis D with the entry inhibitor Myrcludex B: first results of a phase Ib/IIa study. J Hepatol. 2016;65(3):490–8.
4. Blank A, Markert C, Hohmann N, et al. First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor Myrcludex B. J Hepatol. 2016;65(3):483–9.
5. European Medicines Agency. Hepcludex: EPAR—medicine overview. 2020. https://www.ema.europa.eu. Accessed 31 Aug 2020.
Cited by
83 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献